SCHEMBL21667365

SCHEMBL21667365

CC(C)n1c(=O)cc(NCCc2ccccc2)[nH]c1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.70
▸ TP53 P04637 1/20 0.70
▸ CYP3A4 P08684 1/20 0.59
▸ CYP2B6 P20813 1/20 0.59
▸ GPR84 Q9NQS5 6/20 0.53
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ GLA P06280 1/20 0.46
▸ HSD17B10 Q99714 1/20 0.46
▸ TAAR1 Q96RJ0 4/20 0.45
▸ TYMP P19971 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ LMNA P02545 1/20 0.45
▸ NSD2 O96028 1/20 0.41
▸ HSP90AA1 P07900 1/20 0.41
▸ G6PD P11413 1/20 0.41
▸ CCR6 P51684 1/20 0.41
▸ HKDC1 Q2TB90 1/20 0.41
▸ TLR9 Q9NR96 1/20 0.41
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21667334 0.92 SMN1; SMN2 (0.60) SMN1; SMN2TP53CYP3A4CYP2B6GPR84
SCHEMBL20716038 0.86 CYP3A4 (0.61) SMN1; SMN2TP53CYP3A4CYP2B6GPR84
SCHEMBL16321231 0.82 CYP3A4 (0.63) SMN1; SMN2TP53CYP3A4CYP2B6MEN1
SCHEMBL16321233 0.82 CYP3A4 (0.63) SMN1; SMN2TP53CYP3A4CYP2B6MEN1
SCHEMBL16321942 0.79 CYP3A4 (0.66) SMN1; SMN2TP53CYP3A4CYP2B6MEN1
SCHEMBL16321940 0.79 CYP3A4 (0.66) SMN1; SMN2TP53CYP3A4CYP2B6MEN1
SCHEMBL21667347 0.77 CYP3A4 (0.50) SMN1; SMN2TP53CYP3A4CYP2B6MEN1
SCHEMBL21667306 0.77 CYP3A4 (0.50) SMN1; SMN2TP53CYP3A4CYP2B6GPR84
SCHEMBL21667198 0.77 CYP3A4 (0.50) SMN1; SMN2TP53CYP3A4CYP2B6MEN1
SCHEMBL21667374 0.76 CYP3A4 (0.52) SMN1; SMN2TP53CYP3A4CYP2B6GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117897155-A Use of PPARgamma agonists or MPC inhibitors for the treatment of primary, congenital diseases of the heart muscle (cardiomyopathy) 预防治疗有限公司 2024-04-16 — — CN disclosed
EP-3702352-A1 PYRIMIDINEDIONE COMPOUND AGAINST CARDIAC CONDITIONS Myokardia, Inc. (US) 2020-09-02 — — EP disclosed
EP-3010910-B1 PYRIMIDINEDIONE COMPOUNDS AGAINST CARDIAC CONDITIONS MYOKARDIA INC (US) 2020-02-05 — — EP disclosed
Send feedback